Twist Bioscience stock rises 14.42 percent near yearly high

Twist Bioscience stock was trading at USD 181.36 on Nasdaq on September 24, 2026 at 3:33 p.m. ET, up 14.42 percent. The move follows the company joining Eli Lilly's TuneLab platform for AI-supported antibody drug discovery, an agreement listed by Twist Bioscience on September 16, 2026.

Revenue clears the estimate

The latest operating figures show why the stock has attracted attention. For fiscal Q3 2026, revenue reached USD 118.4 million, compared with a Wall Street estimate of USD 114.54 million, according to Investing.com. The company also delivered its 14th consecutive quarter of sequential revenue growth, with sales up 23 percent from the prior year.

The earnings picture remains more demanding than the sales trajectory. Adjusted EPS was a loss of USD 0.56 in fiscal Q3 2026, wider than the expected loss of USD 0.48, so revenue growth has not yet translated into adjusted profitability.

AI partnership adds a new angle

The Lilly agreement connects Twist's antibody characterization data and services with TuneLab, Lilly's AI and machine learning drug discovery platform. That expands the commercial use case beyond DNA synthesis products and gives the stock a concrete partnership event alongside its latest quarterly growth.

Investors are therefore weighing two different numbers: USD 118.4 million of quarterly revenue and a USD 0.56 adjusted per-share loss. The contrast matters because the share price is already close to its annual peak.

Stock approaches yearly high

At USD 181.36 on September 24, 2026, Twist Bioscience stock was 0.33 percent below its 52-week high of USD 181.96. Its 52-week low was USD 23.30, leaving the current quote 678.2 percent above that level.

The market capitalization stood at USD 11,293,342,381 at the same timestamp. The valuation now reflects strong sales expansion, while the latest loss figure keeps profitability as the central financial checkpoint.